<unk> , sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Developed by Global Blood Therapeutics,<unk>  is the first hemoglobin oxygen-affinity modulator.<unk>  has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. It has a safe profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity. In November 2019,<unk>  received accelerated approval in the United States for the treatment of sickle cell disease (SCD) for those twelve years of age and older. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. In December 2021,<unk>  received accelerated approval in the United States for the treatment of sickle cell disease (SCD) for those aged four to eleven years.
Voxelotor
Neuromere
Surgisphere
Extrapyramidal system
Sudomotor
Optician
Language center
Biomesh